Bayer drug fails Phase 3 trial

|About: Bayer A.G. ADR (BAYRY)|By:, SA News Editor

Bayer's (BAYRY) cancer drug Nexavar (sorafenib)  fails to meet its primary endpoint of improving recurrence-free survival.

The target patient group is liver cancer patients who had no detectable disease after surgery.

The company states that it remains committed to exploring the full potential of the drug in all stages of liver cancer.